Sungwoo Choi1,2, Bingning Dong3, Chih-Chun Janet Lin4, Mi Jeong Heo3, Kang Ho Kim3, Zhen Sun3, Martin Wagner5, Nagireddy Putluri3,6, Jae Myoung Suh7,2, Meng C Wang1,4, David D Moore1,3. 1. Program in Developmental Biology, Baylor College of Medicine, Houston, TX. 2. Institute of Natural Science, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea. 3. Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX. 4. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX. 5. Division of Gastroenterology and Hepatology, Medical University Graz, Graz, Austria. 6. Dan L. Duncan Cancer Center and Advanced Technology Core and Alkek Center for Molecular Discovery, Baylor College of Medicine, Houston, TX. 7. Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Abstract
BACKGROUND AND AIMS: Liver receptor homolog-1 (LRH-1; NR5A2) is a nuclear receptor that regulates metabolic homeostasis in the liver. Previous studies identified phosphatidylcholines as potential endogenous agonist ligands for LRH-1. In the liver, distinct subsets of phosphatidylcholine species are generated by two different pathways: choline addition to phosphatidic acid through the Kennedy pathway and trimethylation of phosphatidylethanolamine through phosphatidylethanolamine N-methyl transferase (PEMT). APPROACH AND RESULTS: Here, we report that a PEMT-LRH-1 pathway specifically couples methyl metabolism and mitochondrial activities in hepatocytes. We show that the loss of Lrh-1 reduces mitochondrial number, basal respiration, beta-oxidation, and adenosine triphosphate production in hepatocytes and decreases expression of mitochondrial biogenesis and beta-oxidation genes. In contrast, activation of LRH-1 by its phosphatidylcholine agonists exerts opposite effects. While disruption of the Kennedy pathway does not affect the LRH-1-mediated regulation of mitochondrial activities, genetic or pharmaceutical inhibition of the PEMT pathway recapitulates the effects of Lrh-1 knockdown on mitochondria. Furthermore, we show that S-adenosyl methionine, a cofactor required for PEMT, is sufficient to induce Lrh-1 transactivation and consequently mitochondrial biogenesis. CONCLUSIONS: A PEMT-LRH-1 axis regulates mitochondrial biogenesis and beta-oxidation in hepatocytes.
BACKGROUND AND AIMS: Liver receptor homolog-1 (LRH-1; NR5A2) is a nuclear receptor that regulates metabolic homeostasis in the liver. Previous studies identified phosphatidylcholines as potential endogenous agonist ligands for LRH-1. In the liver, distinct subsets of phosphatidylcholine species are generated by two different pathways: choline addition to phosphatidic acid through the Kennedy pathway and trimethylation of phosphatidylethanolamine through phosphatidylethanolamine N-methyl transferase (PEMT). APPROACH AND RESULTS: Here, we report that a PEMT-LRH-1 pathway specifically couples methyl metabolism and mitochondrial activities in hepatocytes. We show that the loss of Lrh-1 reduces mitochondrial number, basal respiration, beta-oxidation, and adenosine triphosphate production in hepatocytes and decreases expression of mitochondrial biogenesis and beta-oxidation genes. In contrast, activation of LRH-1 by its phosphatidylcholine agonists exerts opposite effects. While disruption of the Kennedy pathway does not affect the LRH-1-mediated regulation of mitochondrial activities, genetic or pharmaceutical inhibition of the PEMT pathway recapitulates the effects of Lrh-1 knockdown on mitochondria. Furthermore, we show that S-adenosyl methionine, a cofactor required for PEMT, is sufficient to induce Lrh-1 transactivation and consequently mitochondrial biogenesis. CONCLUSIONS: A PEMT-LRH-1 axis regulates mitochondrial biogenesis and beta-oxidation in hepatocytes.
Authors: Ainara Cano; Xabier Buqué; Maite Martínez-Uña; Igor Aurrekoetxea; Ariane Menor; Juan L García-Rodríguez; Shelly C Lu; M Luz Martínez-Chantar; José M Mato; Begoña Ochoa; Patricia Aspichueta Journal: Hepatology Date: 2011-12 Impact factor: 17.425
Authors: Maaike H Oosterveer; Chikage Mataki; Hiroyasu Yamamoto; Taoufiq Harach; Norman Moullan; Theo H van Dijk; Eduard Ayuso; Fatima Bosch; Catherine Postic; Albert K Groen; Johan Auwerx; Kristina Schoonjans Journal: J Clin Invest Date: 2012-07-09 Impact factor: 14.808
Authors: Jiannan Song; Kerry Ann da Costa; Leslie M Fischer; Martin Kohlmeier; Lester Kwock; Shuli Wang; Steven H Zeisel Journal: FASEB J Date: 2005-08 Impact factor: 5.191
Authors: Elena P Sablin; Raymond D Blind; Rubatharshini Uthayaruban; Hsiu-Ju Chiu; Ashley M Deacon; Debanu Das; Holly A Ingraham; Robert J Fletterick Journal: J Struct Biol Date: 2015-09-28 Impact factor: 2.867
Authors: Martin Wagner; Sungwoo Choi; Katrin Panzitt; Jennifer L Mamrosh; Jae Man Lee; Alex Zaufel; Rui Xiao; Ruth Wooton-Kee; Marcus Ståhlman; Christopher B Newgard; Jan Borén; David D Moore Journal: Hepatology Date: 2015-10-10 Impact factor: 17.425
Authors: Jae Man Lee; Yoon Kwang Lee; Jennifer L Mamrosh; Scott A Busby; Patrick R Griffin; Manish C Pathak; Eric A Ortlund; David D Moore Journal: Nature Date: 2011-05-25 Impact factor: 49.962
Authors: Diego A Miranda; William C Krause; Amaury Cazenave-Gassiot; Miyuki Suzawa; Hazel Escusa; Juat Chin Foo; Diyala S Shihadih; Andreas Stahl; Mark Fitch; Edna Nyangau; Marc Hellerstein; Markus R Wenk; David L Silver; Holly A Ingraham Journal: JCI Insight Date: 2018-03-08
Authors: Suzanne G Mays; Józef Stec; Xu Liu; Emma H D'Agostino; Richard J Whitby; Eric A Ortlund Journal: Sci Rep Date: 2020-12-17 Impact factor: 4.379